On November 10, 2025, Galecto, Inc. completed its acquisition of Damora Therapeutics, including issuing 265,309 shares of common stock and 20,607 shares of preferred stock in the transaction, with a total estimated value of $285 million for the financing. This merger does not require stockholder approval and updates on executive changes and governance were also made with new appointments to the board.